|
Eine Ebene nach oben |
Gruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 21
2023
Weiss, L.; Heinrich, K.; Zhang, D.; Dorman, K.; Rühlmann, K.; Hasselmann, K.; Klauschen, F.; Kumbrink, J.; Jung, A.; Rudelius, M.; Mock, A.; Ormanns, Steffen 
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
ORCID: https://orcid.org/0000-0002-0754-9034; Kunz, W. G.; Roessler, D.; Beyer, G.; Corradini, S.; Heinzerling, L.; Haas, M.; Bergwelt-Baildon, Michael von ORCID: https://orcid.org/0000-0002-1952-052X; Boeck, S.; Heinemann, Volker ORCID: https://orcid.org/0000-0002-1349-3321 und Westphalen, C. B. ORCID: https://orcid.org/0000-0002-5310-3754
(2023):
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
In: Journal of Cancer Research and Clinical Oncology, Bd. 149, Nr. 11: S. 8225-8234
[PDF, 623kB]
2022
Kruger, S. F.; Lohneis, A.; Abendroth, A.; Berger, A. W.; Ettrich, T. J.; Waidmann, O.; Kapp, M.; Steiner, B.; Kumbrink, J.; Reischer, A.; Haas, M.; Westphalen, C. B.; Zhang, D.; Miller-Phillips, L.; Burger, P. J.; Kobold, S.; Werner, J.; Subklewe, M.; Bergwelt-Baildon, M. von; Kunzmann, V.; Seufferlein, T.; Siveke, J. T.; Sinn, M.; Heinemann, V.; Ormanns, S. und Boeck, S.
(2022):
Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study.
In: ESMO Open, Bd. 7, Nr. 1, 100388
Lim, K. H. J.; Murali, K.; Thorne, E.; Punie, K.; Kamposioras, K.; Oing, C.; O'Connor, M.; Elez, E.; Amaral, T.; Garrido, P.; Lambertini, M.; Devnani, B.; Westphalen, C. B.; Morgan, G.; Haanen, J. B. A. G.; Hardy, C. und Banerjee, S.
(2022):
The impact of COVID-19 on oncology professionals-one year on: lessons learned from the ESMO Resilience Task Force survey series.
In: ESMO Open, Bd. 7, Nr. 1, 100374
Pretzsch, E.; Niess, H.; Boesch, F.; Westphalen, C. B.; Jacob, S.; Neumann, J.; Werner, J.; Heinemann, V. und Angele, M. K.
(2022):
Age and metastasis - How age influences metastatic spread in cancer. Colorectal cancer as a model.
In: Cancer Epidemiology, Bd. 77, 102112
Adashek, J. J.; Subbiah, V.; Westphalen, C. B.; Naing, A.; Kato, S. und Kurzrock, R.
(2022):
Cancer: slaying the nine-headed Hydra.
In: Annals of Oncology, Bd. 34, Nr. 1: S. 61-69
2021
Banerjee, S.; Lim, K. H. J.; Murali, K.; Kamposioras, K.; Punie, K.; Oing, C.; O'Connor, M.; Thorne, E.; Devnani, B.; Lambertini, M.; Westphalen, C. B.; Garrido, P.; Amaral, T.; Morgan, G.; Haanen, J. B. A. G. und Hardy, C.
(2021):
The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration.
In: Esmo Open, Bd. 6, Nr. 2, 100058
Westphalen, C. B.; Krebs, M. G.; Le Tourneau, C.; Sokol, E. S.; Maund, S. L.; Wilson, T. R.; Jin, D. X.; Newberg, J. Y.; Fabrizio, D.; Veronese, L.; Thomas, M. und de Braud, F.
(2021):
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population.
In: Npj Precision Oncology, Bd. 5, Nr. 1, 69
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Häbe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Böck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & Translational Oncology, Bd. 23, Nr. 11: S. 2394-2401
Puhr-Westerheide, D.; Westphalen, C. B. und Streitparth, F.
(2021):
Integrierte Diagnostik beim CUP-Syndrom. Computertomographie, Magnetresonanztomographie und bildgesteuerte Biopsie.
In: Onkologe, Bd. 27, Nr. 7: S. 628-636
Lim, K. H. J.; Murali, K.; Kamposioras, K.; Punie, K.; Oing, C.; O'Connor, M.; Thorne, E.; Amaral, T.; Garrido, P.; Lambertini, M.; Devnani, B.; Westphalen, C. B.; Morgan, G.; Haanen, J. B. A. G.; Hardy, C. und Banerjee, S.
(2021):
Theconcerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II.
In: Esmo Open, Bd. 6, Nr. 4, 100199
Haas, M.; Waldschmidt, D. T.; Stahl, M.; Reinacher-Schick, A.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kaiser, F.; Kanzler, S.; Frickhofen, N.; Seufferlein, T.; Dechow, T.; Mahlberg, R.; Malfertheiner, P.; Illerhaus, G.; Kubicka, S.; Abdul-Ahad, A.; Snijder, R.; Kruger, S.; Westphalen, C. B.; Held, S.; Bergwelt-Baildon, M. von; Boeck, S. und Heinemann, V.
(2021):
Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of the Arbeitsgemeinschaft Internistische Onkologie with an integrated analysis of the 'burden of therapy' method.
In: European Journal of Cancer, Bd. 146: S. 95-106
Sams, L.; Kruger, S.; Heinemann, V.; Bararia, D.; Haebe, S.; Alig, S.; Haas, M.; Zhang, D.; Westphalen, C. B.; Ormanns, S.; Metzger, P.; Werner, J.; Weigert, O.; von Bergwelt-Baildon, M.; Rataj, F.; Kobold, S. und Boeck, S.
(2021):
Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
In: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
[PDF, 1MB]
2020
Mosele, F.; Remon, J.; Mateo, J.; Westphalen, C. B.; Barlesi, F.; Lolkema, M. P.; Normanno, N.; Scarpa, A.; Robson, M.; Meric-Bernstam, F.; Wagle, N.; Stenzinger, A.; Bonastre, J.; Bayle, A.; Michiels, S.; Bieche, I; Rouleau, E.; Jezdic, S.; Douillard, J-Y; Reis-Filho, J. S.; Dienstmann, R. und Andre, F.
(2020):
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
In: Annals of Oncology, Bd. 31, Nr. 11: S. 1491-1505
2019
Westphalen, C. B.; Preinfalk, A.; Krüger, S.; Haas, M.; Renz, B. W.; Riener, M.-O.; Weber, A.; Kirchner, T.; Werner, J.; Heinemann, V; Bergwelt-Baildon, M. von; Baba, H. A.; Siveke, J. T.; Ormanns, S. und Böck, S.
(2019):
Neurotrophic tropomyosin receptor kinase (NTRK) and nerve growth factor (NGF) are not expressed in Caucasian patients with biliary tract cancers: pooled data from three independent cohorts.
In: Clinical & Translational Oncology, Bd. 21, Nr. 8: S. 1108-1111
2018
Haas, M.; Siveke, J. T.; Schenk, M.; Lerch, M. M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Kanzler, S.; Kunzmann, V.; Ettrich, T. J.; Kruger, S.; Westphalen, C. B.; Held, S.; Heinemann, V. und Böck, S.
(2018):
Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the 'Arbeitsgemeinschaft Internistische Onkologie'.
In: European Journal of Cancer, Bd. 94: S. 95-103
Krüger, S.; Heinemann, V.; Ross, C.; Diehl, F.; Nagel, D.; Ormanns, S.; Liebmann, S.; Prinz-Bravin, I.; Westphalen, C. B.; Haas, M.; Jung, A.; Kirchner, T.; Bergwelt-Baildon, M. von; Böck, S. und Holdenrieder, S.
(2018):
Repeated (mut)KRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
In: Annals of Oncology, Bd. 29, Nr. 12: S. 2348-2355
Holch, J. W.; Ricard, I.; Stintzing, Sebastian; Fischer von Weikersthal, Ludwig; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Heintges, T.; Kahl, C.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Jelas, I.; Modest, D. P.; Westphalen, C. B.; Einem, J. C. von; Michl, M. und Heinemann, V.
(2018):
Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
In: European Journal of Cancer, Bd. 106: S. 115-125
2017
Haas, M.; Böck, S.; Siveke, J. T.; Schenk, M.; Lerch, M.; Caca, K.; Freiberg-Richter, J.; Fischer von Weikersthal, L.; Kullmann, F.; Reinacher-Schick, A.; Fuchs, M.; Ettrich, T. J.; Kanzler, S.; Kunzmann, V.; Kruger, S.; Westphalen, C. B.; Held, S. und Heinemann, V.
(2017):
Efficacy of gemcitabine plus erlotinib for rash-positive metastatic pancreatic cancer patients eligible for treatment with FOLFIRINOX - a prospective phase II trial of the "Arbeitsgemeinschaft Internistische Onkologie" - AIO.
In: Oncology Research and Treatment, Bd. 40: S. 207-208
Kruger, S.; Ormanns, S.; Rösgen, V.; Legenstein, M.-L.; Haas, M.; Westphalen, C. B.; Düwell, P.; Schnurr, M.; Heinemann, V.; Kirchner, T. und Böck, S.
(2017):
IDO1 expression as biomarker in erlotinib-treated patients with advanced pancreatic cancer: translational results from the AIO-PK0104 phase III trial.
In: Oncology Research and Treatment, Bd. 40: S. 235
Modest, Dominik P.; Ricard, Ingrid; Stintzing, Sebastian; Fischer von Weikersthal, L.; Decker, T.; Kiani, A.; Vehling-Kaiser, U.; Al-Batran, S.-E.; Heintges, T.; Kahl, C.; Seipelt, G.; Kullmann, F.; Scheithauer, W.; Moehler, M.; Westphalen, C. B.; Holch, Julian W.; Einem, J. C. von; Held, S. und Heinemann, Volker
(2017):
Evaluation of survival across several treatment lines in
metastatic colorectal cancer: analysis of the FIRE-3 trial (AIO KRK0306).
In: European Journal of Cancer, Bd. 84: S. 262-269
2016
Quante, A. S.; Ming, C.; Rottmann, Miriam; Engel, Jutta; Boeck, S.; Heinemann, V.; Westphalen, C. B. und Strauch, K.
(2016):
Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.
In: Cancer Medicine, Bd. 5, Nr. 9: S. 2649-2656